heart

Barry Massie Barry Massie, San Francisco VA Medical Center COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment a

George Sopko

Ernst Rietzschel Jennifer Mieres REFERENCE: News Briefing, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 ERNST RIETZSCHEL, University of Gh

Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u

Philip Barter Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 PHILIP BA

Ake Hjalmarson Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 AKE HJAL

Gordon Tomaselli Daniel Jones REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GORDON TOMASELLI, Johns Hopkins Universit

Anthony Fung REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida ANTHONY FUNG, University of British Columbia, Vanc

Laura Mauri Raymond Gibbons REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LAURA MAURI, Brigham and Woman’s Hospit

REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LESLEE SHAW, Emory University, Atlanta COMMENT: DANI

Edmond Cronin REFERENCE: Abstract 3506, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria EDMOND CRONIN, Cork University Hospital Study data that support banning smoking in

Nilesh Samani REFERENCE: N Engl J Med 2007; 357: 443-53 NILESH SAMANI, University of Leicester UK Previously unrecognised DNA segments in human genes have been found to significantly increase the risk

NILESH SAMANI, Glenfield Hospital, Leicester REFERENCE: Lancet 2007; 369:107 A new genetic test could help predict which individuals will develop coronary heart disease among those with similar conven

Thorsten Dill Simon Hoerstrup Harvey White REPAIR-AMI Study: Bone Marrow Cells Improve Ejection Fraction, Reduce Remodeling REFERENCE: Abstract: 3770 THORSTEN DILL, Kerckhoff-Klinik, Bad Nauheim Proge

Thomas Gaziano, Brigham & Womens’ Hospital, Boston REFERENCE: Lancet 2006; 368: 679-86 Heart disease is currently the leading cause of death in less developed nations but it can be prevented

Germano Di Sciascio, Campus Biomedico University of Rome American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The anti-inflammatory action of statins may be causing yet

Donald Redelmeier, University of Toronto Abstract: Lancet 2006; 367:413 Treatment with the lipid lowering agents statins reduced the incidence of sepsis among a large group of patients with cardiovasc

Olivier Bertrand The use of abciximab perfusion after stenting was questioned at the American Heart Association meeting in Dallas. The EASY study found bolus administration of glycoprotein 2B3A inhibi

Volker Schächinger Regeneration of the heart has been achieved by using bone-marrow derived stem cells after myocardial infarction among 200 patients. Volker Schächinger, University of Frankfurt. [a

David Wood Heart disease patients need to change lifestyle and not just take medicines. That’s the message in Stockholm from the EuroAction Project, which is investigating the potential of a nur

Caroline Daly The Euroheart survey has found significant differences in both diagnosis and treatment of heart disease in women as compared with men. Audio Medica asked Caroline Daly of London’s

John Cleland Cardiac resynchronisation has proved even more beneficial in severe heart failure than was proven a year ago by early results from the CARE-HF study. At the European Cardiology meeting in

Ronnie Willenheimer It could be just as good to start treatment for heart failure with a beta blocker first and subsequently use an ACE inhibitor, as the more convetional use of an ACE inhibitor first